MLAB · Business segments
Mesa Labs (MLAB) revenue by segment
Where Mesa Labs’s revenue comes from, as reported in its SEC filings.
Latest quarter: June 30, 2026
Total revenue on the income statement: $60.1M.
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $29.7M | 49.5% |
| Other | $25M | 41.5% |
| China | $5.4M | 9.0% |
Revenue by Segment
| Line | Revenue | Share |
|---|---|---|
| Sterilization and Disinfection Control | $24.5M | 40.7% |
| Calibration Solutions | $13.3M | 22.1% |
| Biopharmaceutical Development | $12.1M | 20.1% |
| Clinical Genomics | $10.3M | 17.1% |
Latest year: March 31, 2026
Total revenue on the income statement: $249.1M.
Revenue by Product
| Line | Revenue | Share |
|---|---|---|
| Product | $203.4M | 81.6% |
| Service | $45.7M | 18.4% |
Revenue by Geography
| Line | Revenue | Share |
|---|---|---|
| United States | $116.9M | 46.9% |
| Other | $111.8M | 44.9% |
| China | $20.4M | 8.2% |
Revenue by Segment
| Line | Revenue | Share |
|---|---|---|
| Sterilization and Disinfection Control | $101.6M | 40.8% |
| Calibration Solutions | $53.6M | 21.5% |
| Biopharmaceutical Development | $48.6M | 19.5% |
| Clinical Genomics | $45.4M | 18.2% |
Reading notes
Share is each line’s part of that breakdown. Margin is the company’s reported segment operating income divided by that segment’s revenue. Companies define segment profit differently and may re-cut segments over time, so a company’s lines can differ between years. Breakdowns that do not add up to within 5% of reported revenue are left out.